NICE recommends generic naftidrofuryl oxalate over Merck's branded Praxilene
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute in England and Wales, has today issued draft guidance recommending naftidrofuryl oxalate for treating intermittent claudication (cramping pains) in patients with peripheral arterial disease (PAD). Although NICE was appraising Merck Serono's brand Praxilene, the institute says that "cheaper, generic preparations" are available and should be used first.
You may also be interested in...
Can Biosimilar Orphans Increase Health System Sustainability In The UK?
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Success For Dutch Parallel Registration and Reimbursement Pilot
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
Need a specific report? 1000+ reports available
Buy Reports